HSP90B2P and non-small cell lung carcinoma: Our finding of a novel role for sulforaphane in modulating EGFR led us to speculate that this agent might be capable of enhancing the therapeutic potential of other HSP inhibitors, such as 17-AAG, in treating TKI-resistant NSCLC.